COMMUNIQUÉS West-GlobeNewswire

Eleos Deepens Post-Acute Care Mission with Home Health, Palliative, and Hospice Care Expansion
28/07/2025
The National Alliance for Care at Home Financial Summit showcases the Eleos expansion for the industry CHICAGO and BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Eleos Health, the market leader in AI for behavioral health, [...]
Carlsmed’s aprevo® Powers First Personalized Cervical Spine Surgery
28/07/2025
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the successful [...]
Full Alliance Group Reports Second Quarter Preliminary results, Unveils Expansion into High-Growth Men's Wellness Personal Care and Health Virility segment, Association Digital Benefits, and Expands its Contract Manufacturing Markets
28/07/2025
TAMPA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) today announced preliminary unaudited revenue results for the second quarter of 2025 and provided an exciting outlook for the [...]
Unity Consortium Announces Publication of Journal of Adolescent Health Supplement: “Expert Perspectives on Adolescent Immunization Platform Visits”
28/07/2025
Supplement provides a timely and comprehensive review of adolescent immunization platforms, offering practical insights for healthcare providers navigating a shifting public health landscape VENTNOR CITY, N.J., July 28 [...]
Global Alzheimer’s Platform Foundation and Genentech Collaborate to Expand Access to Alzheimer’s Research
28/07/2025
WASHINGTON, July 28, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation ® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with [...]
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
28/07/2025
July 28, 2025 News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to [...]
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
28/07/2025
July 28, 2025 News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to [...]
Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference
28/07/2025
HUNTSVILLE, AL, July 28, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
28/07/2025
Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-tumor activity and favorable tolerability [...]
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
28/07/2025
CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, [...]
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
28/07/2025
First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease company On track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, and SGA*, as well [...]
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
28/07/2025
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [ [...]
Cannara Biotech enregistre son chiffre d’affaires et sa rentabilité les plus élevés depuis sa création au troisième trimestre de l’exercice 2025
28/07/2025
Chiffre d’affaires record : le total des produits, déduction faite des taxes d’accise, a augmenté pour atteindre 27,3 millions de dollars au troisième trimestre 2025, soit une hausse de 40 % par rapport à la même [...]
Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025
28/07/2025
Record Revenue: Total revenues, net of excise taxes increased to $27.3 million in Q3 2025, representing a 40% increase over the prior year period. Record Profitability: Gross profit before fair value adjustments rose to [...]
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial
28/07/2025
Hazard Ratios and Improvements in Median PFS are Unprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) Gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) reduced the risk of disease progression or death [...]
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
28/07/2025
Ramat Gan, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the [...]
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
28/07/2025
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
28/07/2025
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of [...]
ProMIS Neurosciences Announces Private Placement Financing
28/07/2025
$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE [...]

Pages